Boston Scientific Corporation (NYSE:BSX) reported fourth-quarter 2025 revenues of $5.29 billion on Wednesday, almost in line with the consensus estimate of $5.28 billion, beating the management guidance of $5.22 billion-$5.31 billion.
The medical technology giant reported adjusted earnings of 80 cents, beating the consensus of 78 cents and the management guidance of 77-79 cents.
Sales increased 15.9% on a reported basis, compared to the company’s guidance range of 14.5%-16.5%, and 14.3% on an operational basis, 12.7% on an organic basis, compared to the company’s guidance range of 11%-13%.
The company’s cardiovascular segment generated sales of $3.48 billion, rising 18.2% (16.5% operationally and 16.1% organically).
Boston Scientific reported a 7% organic growth in interventional Cardiology & Vascular Therapies to $1.20 billion, Watchman sales increased to 29% to $535 million, Electrophysiology sales jumped 35% to $890 million, and Cardiac Rhythm Management sales were up 1% to $587 million.
MedSurg segment revenues increased to $1.81 billion, a 11.7% rise (10.2% operationally and 6.5% organically).
Endoscopy led the way with a 10.1% increase in sales of $760 million. Neuromodulation sales increased 11.1% to $332 million, and Urology sales increased 13.8% to $717 million.
The company reported an adjusted gross margin of 70.7% and an operating margin of 27.3%, almost unchanged from a year ago.
Fiscal 2026 Outlook
Boston Scientific forecasts net sales growth of approximately 10.5%-11.5% in 2026 on a reported basis, and 10%-11% organically.
The sales are expected to be between $22.18 billion-$22.38 billion, versus the consensus of $22.37 billion.
The company estimates adjusted earnings of $3.43 to $3.49 compared to the consensus of $3.47 per share.
Fiscal Q1 2026 Outlook
The company expects net sales growth of approximately 10.5%-12% in the first quarter of 2026 on a reported basis, and 8.5%-10.0% organically, equivalent to sales of $5.13 billion-$5.22 billion, compared to the consensus of $5.20 billion.
The medtech giant expects adjusted earnings of 78-80 cents versus the consensus of 79 cents.
Boston Scientific expects foreign exchange to boost first-quarter results by about 200 basis points, a company executive said Wednesday.
AXIOS Stent Safety Issue Adds Overhang
In January, the U.S. Food and Drug Administration said it is aware that Boston Scientific has advised customers to remove certain AXIOS stents and electrocautery-enhanced delivery systems from use and distribution after reports of deployment and expansion problems that could pose a high risk to patients.
According to the agency, the company sent a letter on Dec. 19, 2025, instructing customers to immediately stop using and distributing the affected devices. Boston Scientific reported that some AXIOS systems have shown increased difficulty in stent deployment during procedures, though the issue does not affect stents that were already successfully implanted.
As of Dec. 23, the company had reported 167 serious injuries and three deaths associated with the issue. The devices are used for endoscopic drainage of pancreatic pseudocysts and walled-off necrosis, as well as gallbladder drainage in high-risk patients with acute cholecystitis.
Boston Scientific instructed healthcare facilities to remove the products from inventory and return them, while the FDA said it is actively reviewing the matter and will provide updates as new information becomes available.
BSX Price Action: Boston Scientific shares were down 15.76% at $77.18 at the time of publication on Wednesday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Photo via Shutterstock
Recent Comments